Gossamer Bio adds Greg Ciongoli to board and audit committee

Gossamer Bio, Inc. said its board appointed Gregory A. Ciongoli as a director effective September 16, 2026, with an initial term running until the company's 2027 annual meeting of stockholders, and also placed him on the Audit Committee. The board acted on the recommendation of the Nominating and Corporate Governance Committee under the company's amended and restated bylaws.¹

Ciongoli, 51, founded Adiumentum Capital Management, a Boston investment firm where he has been managing partner starting in April 2024. Before that he spent from 2007 to 2024 as a partner at the Baupost Group, working across public and private equity investments.¹ He also sits on the boards of REGENXBIO Inc., which he joined in August 2026, Zymeworks, Inc., joined in August 2025, and Atara Biotherapeutics, Inc., where he has been a director since September 2024 and board chair since September 2025.¹

Under Gossamer's director pay program, Ciongoli will get a $40,000 annual cash retainer for board service plus $7,500 for the Audit Committee¹, with an initial equity award to be granted at a future date and amount still to be set by the board¹. The filing noted there is no arrangement between Ciongoli and any other person tied to his appointment¹, and the board found him independent under Nasdaq Global Select Market listing rules¹.

The filing also disclosed that Ciongoli was a purchaser in the company's 2026 private placement, whose initial closing occurred August 24, 2026 under an August 20, 2026 securities purchase agreement¹. Gossamer is developing seralutinib for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.